Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer

Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer is a phase 2 interventional study registered as NCT00551525 by Radiation Therapy Oncology Group, with 67 participants recorded, started 2008-04 and reaching its primary completion in 2014-07. Interventions recorded: Radiotherapy, Samarium 153. Conditions recorded: Prostate Cancer.

Linked to the drug Samarium-153 lexidronam because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.